These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11417352)

  • 1. [Industry-promoted research and the significance principle].
    Klin Monbl Augenheilkd; 2001 May; 218(5):A90-1. PubMed ID: 11417352
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceutical company-sponsored drug trials: what are we to believe?
    Shekelle P
    J Clin Epidemiol; 2010 Feb; 63(2):126-7. PubMed ID: 19836207
    [No Abstract]   [Full Text] [Related]  

  • 3. [Are treatment effects or adverse effects of significance for the association between financing and conclusions in randomized trials?].
    Als-Nielsen BE; Chen W; Gluud CN; Gluud LL
    Ugeskr Laeger; 2004 Apr; 166(18):1676-8. PubMed ID: 15174406
    [No Abstract]   [Full Text] [Related]  

  • 4. Data bases of clinical trials.
    Albrich JM
    N Engl J Med; 1999 Jan; 340(1):65-6. PubMed ID: 9882223
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical company-sponsored drug trials: the system is broken.
    Gartlehner G; Fleg A
    J Clin Epidemiol; 2010 Feb; 63(2):128-9. PubMed ID: 19880288
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparing antipsychotic efficacy.
    Tandon R
    Am J Psychiatry; 2006 Sep; 163(9):1645. PubMed ID: 16946199
    [No Abstract]   [Full Text] [Related]  

  • 7. Industry sponsorship in research and publishing: who is really to blame for perceived bias?
    Amsden GW
    Ann Pharmacother; 2004 Apr; 38(4):714-6. PubMed ID: 14982974
    [No Abstract]   [Full Text] [Related]  

  • 8. [ACCOMPLISH and the risks with company sponsored clinical trials].
    Furberg C
    Lakartidningen; 2009 Feb 11-17; 106(7):450. PubMed ID: 19350775
    [No Abstract]   [Full Text] [Related]  

  • 9. The uncertainty principle and industry-sponsored research.
    Djulbegovic B; Lacevic M; Cantor A; Fields KK; Bennett CL; Adams JR; Kuderer NM; Lyman GH
    Lancet; 2000 Aug; 356(9230):635-8. PubMed ID: 10968436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Independent research should be supported].
    Als-Nielsen B; Gluud C; Gluud LL
    Ugeskr Laeger; 2003 Oct; 165(44):4237; author reply 4237-8. PubMed ID: 14621563
    [No Abstract]   [Full Text] [Related]  

  • 11. Independent clinical trials.
    Maggio A; D'Amico G; Morabito A
    Lancet; 2004 Mar; 363(9414):1080. PubMed ID: 15051304
    [No Abstract]   [Full Text] [Related]  

  • 12. Medscape psychopharmacology today: understanding clinical trials in context.
    Kramer TA
    MedGenMed; 2003 Oct; 5(4):2. PubMed ID: 14745349
    [No Abstract]   [Full Text] [Related]  

  • 13. Large clinical trials in epilepsy: funding by the NIH versus pharmaceutical industry.
    Privitera M
    Epilepsy Res; 2006 Jan; 68(1):52-6. PubMed ID: 16377139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Financial interests characterize published reports on coxiber. Whom can we rely on?].
    Håkansson J
    Lakartidningen; 2002 Oct; 99(40):3930-1. PubMed ID: 12422746
    [No Abstract]   [Full Text] [Related]  

  • 15. The evidence behind our evidence-based decisions: cheques and balances.
    Halkin H
    Isr Med Assoc J; 2006 Jul; 8(7):494-6. PubMed ID: 16889166
    [No Abstract]   [Full Text] [Related]  

  • 16. Industry-sponsored pharmaceutical trials and research ethics boards: are they cloaked in too much secrecy?
    Ferris LE
    CMAJ; 2002 May; 166(10):1279-80. PubMed ID: 12041844
    [No Abstract]   [Full Text] [Related]  

  • 17. Disclosure of competing financial interests and role of sponsors in phase III cancer trials.
    Tuech JJ; Moutel G; Pessaux P; Thoma V; Schraub S; Herve C
    Eur J Cancer; 2005 Oct; 41(15):2237-40. PubMed ID: 16214044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mega-trials for blockbusters.
    Ioannidis JP
    JAMA; 2013 Jan; 309(3):239-40. PubMed ID: 23321760
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug development costs are overstated by the industry].
    Jeppsson A
    Lakartidningen; 2006 Mar 1-7; 103(9):663-4; discussion 664. PubMed ID: 16583545
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative effectiveness reviews and the impact of funding bias.
    Gartlehner G; Fleg A
    J Clin Epidemiol; 2010 Jun; 63(6):589-90. PubMed ID: 20434022
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.